Truist Securities Reiterates Buy Rating on CG Oncology (CGON) following JNJ erda-i data presentation
Tweet Send to a Friend
Truist Securities analyst Greg Renza reiterated a Buy rating and $75.00 price target on CG Oncology (NASDAQ: CGON)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
